JERUSALEM--(BUSINESS WIRE)--Mar. 9, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the launch of the generic equivalent to Pulmicort Respules®1 (budesonide inhalation ...
Aurobindo Pharma Limited on Thursday announced that its wholly owned subsidiary company, Eugia Pharma Specialities Limited, has received final approval from the US Food & Drug Administration (USFDA) ...
AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca's US Patent No. 6,598,603 ("the '603 patent"), protecting PULMICORT RESPULES in ...
Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, announced the launch of the generic equivalent to Pulmicort Respules (budesonide inhalation suspension), 1 mg/2 ml, in the ...
https://www.thehindubusinessline.com/markets/aurobindos-subsidiary-secures-approval-for-budesonide-inhalation-suspension/article67589939.ece Copy Aurobindo Pharma ...
Aurobindo Pharma’s wholly-owned subsidiary company, Eugia Pharma Specialities Ltd, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Budesonide ...
In conjunction with the Court's Order against Teva, AstraZeneca agreed and that it too would halt all sales of its authorized generic budesonide inhalation suspension product and take other necessary ...
Short-term budesonide transnasal nebulization effectively and safely treated patients with chronic rhinosinusitis with nasal polyps when compared with placebo, according to study results. In a double ...
Research and Markets: Investigation Report on China's Budesonide (Pulmicort Respules) Market to 2018
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5rp48m/investigation) has announced the addition of the "Investigation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback